1236357-64-4

Usage

Uses

Used in Organic Synthesis:
1-(4-Bromo-phenyl)-cyclopentanecarboxylic acid methyl ester is used as a building block in the synthesis of pharmaceuticals and bioactive compounds, contributing to the development of novel chemical entities with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(4-Bromo-phenyl)-cyclopentanecarboxylic acid methyl ester is utilized as an intermediate for the synthesis of complex molecular structures with potential medicinal properties, aiding in the advancement of drug discovery.
Used in Chemical Reactions:
1-(4-BroMo-phenyl)-cyclopentanecarboxylic acid Methyl ester is employed as a reagent in various chemical reactions, such as Suzuki-Miyaura coupling, Heck coupling, and Sonogashira coupling, facilitating the formation of new carbon-carbon and carbon-heteroatom bonds, which are crucial for the synthesis of a wide range of organic compounds.
Used in Drug Development:
Due to its unique structural features, 1-(4-Bromo-phenyl)-cyclopentanecarboxylic acid methyl ester may have potential applications in the development of new drugs, particularly in the areas of pharmaceuticals and agrochemicals, where its properties can be harnessed to create innovative and effective products.
Used in Agrochemical Development:
1-(4-BroMo-phenyl)-cyclopentanecarboxylic acid Methyl ester's structural attributes also make it a candidate for use in the development of new agrochemicals, where it could contribute to the creation of novel products with enhanced efficacy and selectivity in agricultural applications.

Upstream product

• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 110-52-1 1,4-dibromo-butane 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 

Downstream Products

• 1423704-72-6 C₁₉H₂₇BO₄ 
• 1423693-16-6 C₃₂H₃₂N₂O₄S 
• 1423685-78-2 C₃₁H₃₀N₂O₄S 
• 1423693-19-9 C₃₁H₂₉N₂O₄S^(1-)*Na⁽¹⁺⁾ 
• 143328-24-9 1-(4-bromophenyl)cyclopentanecarboxylic acid 

Relevant academic research and scientific papers

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs

The present invention relates to a dihydropyrimidine compound and uses of the dihydropyrimidine compound as drugs, particularly as drugs for treatment and prevention of hepatitis B, particularly to acompound represented by a general formula (I) or (Ia) or an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein each variable is definedin the specification. The invention further relates to uses of the compound represented by a general formula (I) or (Ia) or the enantiomer, the diastereomer, the tautomer, the hydrate, the solvate orthe pharmaceutically acceptable salt thereof as drugs, especially as drugs for treatment and prevention of hepatitis B. The formulas (I) and (Ia) are defined in the specification.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.